Endo to Pay $8 Billion for Par

The deal would create one of the five biggest generic drugmakers in the U.S.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, RAGESOSSIreland-based Endo International announced Monday (May 18) that it has made a deal to purchase Par Pharmaceuticals, a privately-held generic drugmaker headquartered in New York, for $8.05 billion in cash and shares. “This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive gross margin products while also transforming Endo, creating a powerful corporate platform for future growth and strategic [mergers and acquisitions],” Endo president and CEO Rajiv De Silva said in a statement. If completed, the deal would create a firm that will be ranked in the top five generic drugmakers as measured by US sales.

The move is indicative of the rapid growth experienced in the generic drug space. Endo, which makes the painkiller Percocet in addition to several generic pharmaceuticals and over-the-counter medications, moved to Ireland in early 2014 in a tax-inversion deal in which it also acquired Paladin Labs. The company then gobbled up two other firms before failing to take over Salix Pharmaceuticals when a rival company outbid Endo this March. Separately, Mylan Pharmaceuticals last month staved off a $40 billion takeover bid from rival Teva.

Unlike the Mylan/Teva bid, all parties involved in the Endo/Par deal—including the boards and management teams of each company—have approved the transaction. “This is an exciting time of growth and opportunity in the generics and specialty pharmaceutical arenas,” Par CEO Paul ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Bob Grant

    From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio